HRC Stock Overview
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide.
Hill-Rom Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$155.96|
|52 Week High||US$156.22|
|52 Week Low||US$93.34|
|1 Month Change||0.58%|
|3 Month Change||3.16%|
|1 Year Change||65.76%|
|3 Year Change||73.42%|
|5 Year Change||183.15%|
|Change since IPO||604.90%|
Recent News & Updates
Here's Why We Think Hill-Rom Holdings (NYSE:HRC) Is Well Worth Watching
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
|HRC||US Medical Equipment||US Market|
Return vs Industry: HRC exceeded the US Medical Equipment industry which returned 15.2% over the past year.
Return vs Market: HRC exceeded the US Market which returned 21% over the past year.
|HRC Average Weekly Movement||0.9%|
|Medical Equipment Industry Average Movement||8.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: HRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.
Volatility Over Time: HRC's weekly volatility (1%) has been stable over the past year.
About the Company
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. The company operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. It offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment.
Hill-Rom Holdings Fundamentals Summary
|HRC fundamental statistics|
Is HRC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HRC income statement (TTM)|
|Cost of Revenue||US$1.43b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.76|
|Net Profit Margin||8.23%|
How did HRC perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Does HRC pay a reliable dividends?See HRC dividend history and benchmarks
|Hill-Rom Holdings dividend dates|
|Ex Dividend Date||Dec 14 2021|
|Dividend Pay Date||Dec 31 2021|
|Days until Ex dividend||35 days|
|Days until Dividend pay date||18 days|
Does HRC pay a reliable dividends?See HRC dividend history and benchmarks
Is Hill-Rom Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRC ($155.96) is trading below our estimate of fair value ($167.32)
Significantly Below Fair Value: HRC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: HRC is good value based on its PE Ratio (41.5x) compared to the US Medical Equipment industry average (47.1x).
PE vs Market: HRC is poor value based on its PE Ratio (41.5x) compared to the US market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: HRC is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: HRC is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (3.7x).
How is Hill-Rom Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRC's forecast earnings growth (20.4% per year) is above the savings rate (2%).
Earnings vs Market: HRC's earnings (20.4% per year) are forecast to grow faster than the US market (13.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HRC's revenue (4.2% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: HRC's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HRC's Return on Equity is forecast to be low in 3 years time (18.6%).
How has Hill-Rom Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HRC has a large one-off loss of $103.9M impacting its September 30 2021 financial results.
Growing Profit Margin: HRC's current net profit margins (8.2%) are higher than last year (7.7%).
Past Earnings Growth Analysis
Earnings Trend: HRC's earnings have grown by 10.6% per year over the past 5 years.
Accelerating Growth: HRC's earnings growth over the past year (11.4%) exceeds its 5-year average (10.6% per year).
Earnings vs Industry: HRC earnings growth over the past year (11.4%) underperformed the Medical Equipment industry 51.2%.
Return on Equity
High ROE: HRC's Return on Equity (13.2%) is considered low.
How is Hill-Rom Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRC's short term assets ($1.4B) exceed its short term liabilities ($991.2M).
Long Term Liabilities: HRC's short term assets ($1.4B) do not cover its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: HRC's net debt to equity ratio (96.4%) is considered high.
Reducing Debt: HRC's debt to equity ratio has reduced from 173.9% to 110.8% over the past 5 years.
Debt Coverage: HRC's debt is well covered by operating cash flow (22.9%).
Interest Coverage: HRC's interest payments on its debt are well covered by EBIT (7.4x coverage).
What is Hill-Rom Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HRC's dividend (0.62%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: HRC's dividend (0.62%) is low compared to the top 25% of dividend payers in the US market (3.58%).
Stability and Growth of Payments
Stable Dividend: HRC is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: HRC is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: HRC is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Groetelaars (54 yo)
Mr. John P. Groetelaars serves as President, Chief Executive Officer and Director of Hill-Rom Holdings Inc. since May 14, 2018. Mr. Groetelaars served in a variety of progressive roles at C.R. Bard during...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.63M) is below average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: HRC's management team is considered experienced (4.3 years average tenure).
Experienced Board: HRC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hill-Rom Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Hill-Rom Holdings, Inc.
- Ticker: HRC
- Exchange: NYSE
- Founded: 1915
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$10.301b
- Shares outstanding: 66.05m
- Website: https://www.hillrom.com
Number of Employees
- Hill-Rom Holdings, Inc.
- 130 East Randolph Street
- Suite 1000
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/13 23:13|
|End of Day Share Price||2021/12/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.